fbpx
Size of letters 1x
Site color
Image
Additionally
Line height
Letter spacing
Font
Embedded items (videos, maps, etc.)
 

Executive Director of the Clinical Trials Subcommittee joined the conference “Innovative Technologies in Clinical Trials”

17/ 05/ 2024
  The Scientific and Practical Conference “Innovative Technologies in Clinical Trials”, held on May 10 in Kropyvnytskyi, became a platform for highlighting the important topic of restoring new international clinical trials in Ukraine. Iryna Magdik, Executive Director of the EBA Clinical Trials Subcommittee, who was invited as a speaker, emphasized that only joint work of the EBA experts, the State Expert Center (SEC), the Ministry of Health, the Verkhovna Rada of Ukraine, researchers and other stakeholders can restore international clinical trials (CTs) in the current realities. Although the full-scale war unleashed by Russia against Ukraine has had a negative impact on the clinical trials industry, the clinical trials infrastructure in Ukraine has demonstrated its flexibility and efficiency. Despite the difficulties, active clinical trials in the country continue and there is a positive trend in attracting new research centers and approving and starting new trials, as evidenced by the SEC data in the reports on the state of clinical trials in Ukraine, in particular, in the first quarter of 2024, the number of applications for clinical trials increased almost 2 times compared to the first quarter of 2023 (14 and 8, respectively). According to the latest report, no clinical trials or enrollment of new patients was suspended this year. During her speech, Ms. Iryna noted that in order to maintain Ukraines competitiveness in the field of clinical trials, it is important, among other things, to work on reducing and meeting the deadlines for approval and launch of clinical trials, further introducing digitalization and innovative methods of conducting clinical trials, maintaining the quality of trials and patient protection - these are just some of the aspects that will help to realize the potential and return the attention of international sponsors to Ukraine in the current environment. At present, it is very important to demonstrate the ability to conduct trials at a high level and maintain the appropriate quality of their conduct. CTs audits conducted by the SEC are one of the tools for quality assurance. The EBA CTs Subcommittee continues to work actively to improve the regulatory environment for the CTs sector on the path to European integration. Close cooperation and support of all stakeholders is the key to success in the revitalization of CTs in Ukraine.
01/

The Scientific and Practical Conference “Innovative Technologies in Clinical Trials”, held on May 10 in Kropyvnytskyi, became a platform for highlighting the important topic of restoring new international clinical trials in Ukraine. Iryna Magdik, Executive Director of the EBA Clinical Trials Subcommittee, who was invited as a speaker, emphasized that only joint work of the EBA experts, the State Expert Center (SEC), the Ministry of Health, the Verkhovna Rada of Ukraine, researchers and other stakeholders can restore international clinical trials (CTs) in the current realities.

Although the full-scale war unleashed by Russia against Ukraine has had a negative impact on the clinical trials industry, the clinical trials infrastructure in Ukraine has demonstrated its flexibility and efficiency. Despite the difficulties, active clinical trials in the country continue and there is a positive trend in attracting new research centers and approving and starting new trials, as evidenced by the SEC data in the reports on the state of clinical trials in Ukraine, in particular, in the first quarter of 2024, the number of applications for clinical trials increased almost 2 times compared to the first quarter of 2023 (14 and 8, respectively). According to the latest report, no clinical trials or enrollment of new patients was suspended this year.

During her speech, Ms. Iryna noted that in order to maintain Ukraine’s competitiveness in the field of clinical trials, it is important, among other things, to work on reducing and meeting the deadlines for approval and launch of clinical trials, further introducing digitalization and innovative methods of conducting clinical trials, maintaining the quality of trials and patient protection – these are just some of the aspects that will help to realize the potential and return the attention of international sponsors to Ukraine in the current environment. At present, it is very important to demonstrate the ability to conduct trials at a high level and maintain the appropriate quality of their conduct. CTs audits conducted by the SEC are one of the tools for quality assurance.

The EBA CTs Subcommittee continues to work actively to improve the regulatory environment for the CTs sector on the path to European integration. Close cooperation and support of all stakeholders is the key to success in the revitalization of CTs in Ukraine.

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Start
in the Telegram bot
Read articles. Share in social networks

Spelling error report

The following text will be sent to our editors: